Boehringer Ingelheim Italia
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
The Italian branch is one of the pharmaceutical industry’s top 20 companies of the country and counts about 1000 employees.
In 2018 the turnover was 437 million euros.
The Italian Group has three sites in the country, namely, in:
Milan hosting the country headquarters, the Business Unit Human Pharma and Boehringer Ingelheim Animal Health Italia.
Fornovo San Giovanni (Bergamo), where Bidachem S.p.A. is located. This is a strategic chemical production site for the most innovative active principles of the group worldwide.
Noventa Padovana (Padova), production site belonging to the animal health network and focused on avian vaccines.